^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Thrombopoietin receptor agonist

    Related drugs:
    5d
    Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations (clinicaltrials.gov)
    P2, N=25, Suspended, Abhay Singh, MD MPH | Recruiting --> Suspended
    Trial suspension • Tumor mutational burden
    |
    TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    TET2 mutation • Chr del(5q)
    |
    Promacta (eltrombopag)
    13d
    Cyclosporine in hematological disorders: mechanisms, clinical practice and emerging advances. (PubMed, Ann Hematol)
    Cyclosporine A (CsA) functions as a calcineurin inhibitor that perturbs T cell activation via calcineurin-nuclear factor of activated T cells (CaN-NFAT) signaling inhibitors, establishing its central role in hematological therapeutics. The manuscript further elaborates on pharmacological synergies between CsA and novel targeted agents including eltrombopag, ruxolitinib, and immune checkpoint inhibitors, while evaluating its capacity to surmount chemotherapeutic resistance and function as a bridging modality to CAR-T cell infusion. Lastly, we propose tiered management protocols for dose-limiting toxicities (nephrotoxicity and hypertension) and highlight emerging research frontiers in nanoformulation and artificial intelligence-guided therapeutic drug monitoring.
    Review • Journal • IO biomarker
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • NFATC1 (Nuclear Factor Of Activated T Cells 1)
    |
    STAT3 mutation
    |
    Jakafi (ruxolitinib) • Promacta (eltrombopag) • cyclosporin A microemulsion
    13d
    Romiplostim for Oral TPO-RA Resistant ITP (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, The First Affiliated Hospital of Soochow University
    New trial
    |
    Nplate (romiplostim)
    19d
    Avatrombopag for Severe Thrombocytopenia After Liver Transplantation: A Retrospective Cohort Study (clinicaltrials.gov)
    P=N/A, N=134, Completed, Shanghai Zhongshan Hospital
    New trial
    23d
    ITJ(QN)2510: A Multicenter Clinical Study of Romiplostim N01 in the Treatment of Sepsis-related Thrombocytopenia (clinicaltrials.gov)
    P1, N=280, Not yet recruiting, Shanghai 10th People's Hospital
    New P1 trial
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    27d
    A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag (clinicaltrials.gov)
    P=N/A, N=150, Not yet recruiting, Novartis Pharmaceuticals
    New trial • HEOR • Real-world evidence
    |
    Promacta (eltrombopag)
    28d
    N01-A-PICIT-GT: Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors (clinicaltrials.gov)
    P2, N=220, Recruiting, Peking University People's Hospital
    New P2 trial
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    28d
    N01-A-PICIT-GI: Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors (clinicaltrials.gov)
    P2, N=220, Recruiting, Peking University People's Hospital
    New P2 trial
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    1m
    VAY2EXPLORE: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=164, Recruiting, Novartis Pharmaceuticals | Trial completion date: Sep 2030 --> Mar 2027 | Initiation date: Jun 2026 --> Nov 2026 | Trial primary completion date: Dec 2028 --> Mar 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Promacta (eltrombopag) • Nplate (romiplostim) • ianalumab (VAY736)
    1m
    Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients (clinicaltrials.gov)
    P2, N=50, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Initiation date: Jul 2025 --> Dec 2025 | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    1m
    VAY2EXPLORE: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=164, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting | Trial completion date: Mar 2030 --> Sep 2030 | Trial primary completion date: Jun 2028 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Promacta (eltrombopag) • Nplate (romiplostim) • ianalumab (VAY736)
    1m
    A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (clinicaltrials.gov)
    P3, N=58, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd. | N=34 --> 58 | Not yet recruiting --> Recruiting
    Enrollment open • Enrollment change • Trial initiation date